Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 5:13:1003056.
doi: 10.3389/fneur.2022.1003056. eCollection 2022.

Genetic aspects of human prion diseases

Affiliations
Review

Genetic aspects of human prion diseases

Brian S Appleby et al. Front Neurol. .

Abstract

Human prion diseases are rapidly progressive and fatal neurodegenerative conditions caused by a disease-causing isoform of the native prion protein. The prion protein gene (PRNP) encodes for the cellular prion protein, which is the biological substrate for prion disease transmission and neurotoxicity. Human prion diseases have three etiologies: sporadic, genetic, and acquired. PRNP polymorphisms and pathogenic variants play a large role in the frequency, age at onset, and clinicopathologic phenotype of prion diseases. Genetic prion diseases will be covered in detail and information necessary for clinical care, predictive genetic testing, and genetic counseling will be reviewed. Because the prion protein is necessary for transmission and neurotoxicity, many experimental treatments targeting its production are being investigated and hold potential promise as a disease modifying treatment for all forms of prion disease, including asymptomatic mutation carriers. This article will review genetic aspects of human prion disease and their influence on epidemiology, clinicopathologic phenotype, diagnostics, clinical management, and potential treatment approaches.

Keywords: Creutzfeldt-Jakob disease; Gerstmann-Sträussler Scheinker disease; PRNP; fatal familial insomnia; genetic Creutzfeldt–Jakob disease; genetics; prion disease; prion protein.

PubMed Disclaimer

Conflict of interest statement

Author BA has received research funding from CDC, NIH, CJD Foundation, Ionis, and Alector. He has provided consultation for Ionis, Acadia and Sangamo, as well as being the Medical Director for the CJD Foundation. Author SS has received research funding from the CJD Foundation. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

  • [Genetic background of human prion diseases].
    Kovács GG. Kovács GG. Ideggyogy Sz. 2007 Nov 30;60(11-12):438-46. Ideggyogy Sz. 2007. PMID: 18198790 Review. Hungarian.
  • Prion diseases.
    Ironside JW, Ritchie DL, Head MW. Ironside JW, et al. Handb Clin Neurol. 2017;145:393-403. doi: 10.1016/B978-0-12-802395-2.00028-6. Handb Clin Neurol. 2017. PMID: 28987186 Review.
  • Genetic counseling for prion disease: Updates and best practices.
    Goldman JS, Vallabh SM. Goldman JS, et al. Genet Med. 2022 Oct;24(10):1993-2003. doi: 10.1016/j.gim.2022.06.003. Epub 2022 Jul 12. Genet Med. 2022. PMID: 35819418 Review.
  • Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases.
    Schmitz M, Villar-Piqué A, Hermann P, Escaramís G, Calero M, Chen C, Kruse N, Cramm M, Golanska E, Sikorska B, Liberski PP, Pocchiari M, Lange P, Stehmann C, Sarros S, Martí E, Baldeiras I, Santana I, Žáková D, Mitrová E, Dong XP, Collins S, Poleggi A, Ladogana A, Mollenhauer B, Kovacs GG, Geschwind MD, Sánchez-Valle R, Zerr I, Llorens F. Schmitz M, et al. Brain. 2022 Apr 18;145(2):700-712. doi: 10.1093/brain/awab350. Brain. 2022. PMID: 35288744 Free PMC article.
  • Prion diseases.
    Takada LT, Geschwind MD. Takada LT, et al. Semin Neurol. 2013 Sep;33(4):348-56. doi: 10.1055/s-0033-1359314. Epub 2013 Nov 14. Semin Neurol. 2013. PMID: 24234356 Review.

Cited by

References

    1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. (1982) 216:136–44. 10.1126/science.6801762 - DOI - PubMed
    1. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. . Mice devoid of PrP are resistant to scrapie. Cell. (1993) 73:1339–47. 10.1016/0092-8674(93)90360-3 - DOI - PubMed
    1. Sailer A, Büeler H, Fischer M, Aguzzi A, Weissmann C. No propagation of prions in mice devoid of PrP. Cell. (1994) 77:967–8. 10.1016/0092-8674(94)90436-7 - DOI - PubMed
    1. Klug GMJA, Wand H, Simpson M, Boyd A, Law M, Masters CL, et al. . Intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry. (2013) 84:1372–7. 10.1136/jnnp-2012-304820 - DOI - PubMed
    1. Maddox RA, Person MK, Blevins JE, Abrams JY, Appleby BS, Schonberger LB, et al. . Prion disease incidence in the United States, 2003–2015. Neurology. (2020) 94:e153–7. 10.1212/WNL.0000000000008680 - DOI - PubMed

LinkOut - more resources